Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678119 · ClinicalTrials.gov registry record · Phase 2
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
A Phase 2 study of Renal Cell Carcinoma, sponsored by Argos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 14
- Study locations
NCT00678119: Completed Phase 2 study of Renal Cell Carcinoma, sponsored by Argos Therapeutics.
NCT00678119 is a Phase 2 study of Renal Cell Carcinoma that has completed, run by Argos Therapeutics. The registered enrollment target is 25 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (90% lower). The trial reports 14 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00678119, a Phase 2 study of Renal Cell Carcinoma, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 14
- Study locations
Study Summary
Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC.
Conditions Studied
Interventions
- DRUG Sunitinib
- BIOLOGICAL AGS-003
Study Locations (14)
California
- City of Hope - Duarte
- UCLA - Los Angeles
Colorado
- The Urology Center of Colorado - Denver
Georgia
- Emory University - Atlanta
Indiana
- The Indiana University Cancer Center - Indianapolis
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas Hospital - Kansas City
Minnesota
- University of Minnesota Cancer Center - Minneapolis
North Carolina
- Carolina's Medical Center / Blumenthal Cancer Center - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT00678119 record still lists
NCT00678119 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.
NCT00678119 lists 14 locations in 13 states (California, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT00678119 about?
NCT00678119 is a clinical study titled "Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment". Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC.
What is the current status of trial NCT00678119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-01. Estimated completion is 2012-05.
What conditions does trial NCT00678119 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT00678119?
The interventions under investigation include: Sunitinib (DRUG), AGS-003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00678119?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00678119 being conducted?
This trial has 14 study locations across California, Colorado, Georgia, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00678119's enrollment target sits among peer trials
25 101st of 121 higher than 19 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia